ESCMID 2026 — the European Congress of Clinical Microbiology and Infectious Diseases — runs as a major venue for antimicrobial peptide and infectious-disease readouts. Coverage on this site has included Fedora Pharmaceuticals' FPI-2119 lactivicin bactericidal profile against gram-negative organisms, Barnards' neonatal sepsis program targeting Acinetobacter baumannii, and broader AMR surveillance updates.
The conference also surfaces the policy work on stewardship and reimbursement that determines whether AMP candidates reach commercial viability. WHO guideline updates, CDC priority-pathogen lists, and the BARDA/CARB-X funding picture all sit in the ESCMID conversation.
Stories here cover the conference readouts and the policy follow-on. See #amr, #antimicrobial-peptide, and #antibiotic-resistance.
Fedora Pharmaceuticals presented eight posters at ESCMID Global 2026 in Munich today highlighting FPI-2119, a first-in-kind derivative of the lactivicin class for Gram-negative infections. As a non-β-lactam antibiotic, FPI-2119 is not susceptible to β-lactamases. Posters demonstrated concentration-dependent bactericidal activity and low resistance frequency against Pseudomonas aeruginosa, maintained activity against β-lactamase-expressing E. coli strains, and activity against resistant Campylobacter, Salmonella, and Shigella.
The European Society of Clinical Microbiology & Infectious Diseases (ESCMID) Global 2026 opened today at Messe München, running April 17-21 with ~18,000 international participants. Antimicrobial resistance dominates the agenda, with presentations featuring novel antimicrobial peptides, peptide-antibody hybrids, and AI-driven AMP discovery platforms. ESCMID is the largest international clinical microbiology and infectious diseases conference worldwide.
Longhorn Vaccines and Diagnostics presents preclinical data on DRG5-BD11, a bispecific IgM monoclonal antibody targeting bacterial peptidoglycan and HSP16.3 across gram-positive, gram-negative, and mycobacterial pathogens. In vitro assays demonstrated 82% opsonophagocytic killing against E. coli and 74% against Mycobacterium smegmatis, supporting its potential as a broad-spectrum anti-infective for AMR-driven sepsis.